C.M. Bidwell & Associates’s Teva Pharmaceuticals TEVA Stock Holding History

C.M. Bidwell & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-75	Closed	-$1K	–	544
2020 Q3	$1K	Buy	+75	New	+$793	﹤0.01%	445
2018 Q3	–	Sell	-15,150	Closed	-$368K	–	455
2018 Q2	$368K	Buy	+15,150	New	+$309K	0.34%	82
2016 Q4	–	Sell	-42,345	Closed	-$1.95M	–	305
2016 Q3	$1.95M	Buy	+42,345	New	+$2.21M	0.46%	83
2015 Q3	–	Sell	-6,095	Closed	-$360K	–	278
2015 Q2	$360K	Buy	6,095 +30	+0.5%	+$1.85K	0.08%	122
2015 Q1	$378K	Sell	6,065 -9,710	-62%	-$565K	0.08%	107
2014 Q4	$907K	Buy	15,775 +5,005	+46%	+$279K	0.21%	85
2014 Q3	$579K	Buy	10,770 +4,645	+76%	+$246K	0.14%	96
2014 Q2	$321K	Buy	+6,125	New	+$313K	0.07%	114

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

C.M. Bidwell & Associates's TEVA Position: Q4 2020 in Review

C.M. Bidwell & Associates sold out of Teva Pharmaceuticals (TEVA) in Q4 2020, closing a stake of 75 shares — an estimated $1K sold.

C.M. Bidwell & Associates first reported a position in TEVA in Q2 2014 and held it in 8 quarters. The position peaked at $1.95M in Q3 2016. 449 funds tracked by Wall St. Rank hold TEVA as of Q4 2020.

C.M. Bidwell & Associates reported no remaining Teva Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
C.M. Bidwell & Associates sold 75 Teva Pharmaceuticals shares in Q4 2020, an estimated $1K.
C.M. Bidwell & Associates first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 8 quarters.
C.M. Bidwell & Associates's Teva Pharmaceuticals position peaked at $1.95M in Q3 2016.
449 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2020.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2020, filed 16 Feb 2021.